Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan + cisplatin versus etoposide + cisplatin as first-line therapy for extensive-stage small cell lung cancer
ChiCTR-TRC-08000229Phase 4Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of irinotecan, cisplatin and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoints: Time to tumor progression and Overall survival. Started Dec 2008; status: completed.
02
Drugs
irinotecancisplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR-TRC-08000229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-08000229.